{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:32:08Z","timestamp":1793302328405,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070213"],"award-info":[{"award-number":["82070213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12015-026-11228-z","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:32Z","timestamp":1788335072000},"page":"3566-3585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma"],"prefix":"10.1007","volume":"22","author":[{"given":"Shuai","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7274-6774","authenticated-orcid":false,"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"11228_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., & Mateos, M. V. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15, e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"The Lancet Oncology"},{"key":"11228_CR2","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., & Moreau, P. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology, 17, e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"The Lancet Oncology"},{"key":"11228_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., & Brudno, J. N. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25, 625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"11228_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C., Anderson, L. D. Jr., Shah, N., Madduri, D., Berdeja, J., & Lonial, S. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384, 705\u2013716. https:\/\/doi.org\/10.1056\/NEJMoa2024850","journal-title":"New England Journal of Medicine"},{"key":"11228_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., & Madduri, D. (2019). Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine, 380, 1726\u20131737. https:\/\/doi.org\/10.1056\/NEJMoa1817226","journal-title":"New England Journal of Medicine"},{"key":"11228_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., & Cohen, A. D. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. The Lancet, 398, 314\u2013324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8","journal-title":"The Lancet"},{"key":"11228_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., & Hari, P. (2023). Ciltacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. Journal of Clinical Oncology, 41, 1265\u20131274. https:\/\/doi.org\/10.1200\/JCO.22.00842","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR8","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath, S., Martin, T. G., Lin, Y., Cohen, A. D., Raje, N., & Htut, M. (2025). Long-term (\u2265\u20095-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 43, 2766\u20132771. https:\/\/doi.org\/10.1200\/JCO-25-00760","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., & Mateos, M. V. (2023). Ciltacabtagene autoleucel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389, 335\u2013347. https:\/\/doi.org\/10.1056\/NEJMoa2303379","journal-title":"New England Journal of Medicine"},{"key":"11228_CR10","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., & Nooka, A. K. (2023). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 388, 1002\u20131014. https:\/\/doi.org\/10.1056\/NEJMoa2213614","journal-title":"New England Journal of Medicine"},{"issue":"Suppl","key":"11228_CR11","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","volume":"39","author":"LD Anderson Jr","year":"2021","unstructured":"Anderson, L. D. Jr., Munshi, N. C., Shah, N., Madduri, D., Berdeja, J. G., & Lonial, S. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma: updated KarMMa results. Journal of Clinical Oncology, 39(Suppl), 8016. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8016","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl","key":"11228_CR12","doi-asserted-by":"publisher","first-page":"S209","DOI":"10.1016\/S2152-2650(23)01626-9","volume":"7","author":"H Einsele","year":"2023","unstructured":"Einsele, H., Goldschmidt, H., & Dimopoulos, M. A. (2023). Idecabtagene vicleucel versus standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: subgroup analyses from KarMMa-3. HemaSphere, 7(Suppl), S209. https:\/\/doi.org\/10.1016\/S2152-2650(23)01626-9","journal-title":"HemaSphere"},{"key":"11228_CR13","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K., Sidana, S., Peres, L. C., Colin, E., Chun, I., & Shune, L. (2023). Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. Journal of Clinical Oncology, 41, 2087\u20132097. https:\/\/doi.org\/10.1200\/JCO.22.01365","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR14","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/bjh.19302","volume":"204","author":"D Dima","year":"2024","unstructured":"Dima, D., Davis, J. A., Wood, W. A., Munshi, P. N., Gauthier, J., & Cohen, A. D. (2024). Standard-of-care idecabtagene vicleucel for patients with relapsed\/refractory multiple myeloma who would have been ineligible for KarMMa. British Journal of Haematology, 204, 2208\u20132217. https:\/\/doi.org\/10.1111\/bjh.19302","journal-title":"British Journal of Haematology"},{"key":"11228_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1182\/blood.2024026216","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana, S., Patel, K. K., Peres, L. C., Gagelmann, N., Dima, D., & Ahmed, N. (2025). Standard-of-care idecabtagene vicleucel in relapsed\/refractory multiple myeloma: a CIBMTR analysis. Blood, 145, 1352\u20131362. https:\/\/doi.org\/10.1182\/blood.2024026216","journal-title":"Blood"},{"key":"11228_CR16","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana, S., Patel, K. K., Peres, L. C., Gagelmann, N., Dima, D., & Ahmed, N. (2025). Safety and efficacy of standard-of-care ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. Blood, 145, 1363\u20131374. https:\/\/doi.org\/10.1182\/blood.2024025945","journal-title":"Blood"},{"key":"11228_CR17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen, D. K., Peres, L. C., Dima, D., Richards, A., Shune, L., & Afrough, A. (2025). Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 43, 1597\u20131609. https:\/\/doi.org\/10.1200\/JCO-24-01730","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","volume":"109","author":"S Sidana","year":"2024","unstructured":"Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., & Khouri, J. (2024). Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment. Haematologica, 109, 777\u2013786. https:\/\/doi.org\/10.3324\/haematol.2023.283940","journal-title":"Haematologica"},{"key":"11228_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar, S., Nadeem, O., Bumma, N., Atrash, S., Bansal, R., & Dhakal, B. (2024). Idecabtagene vicleucel in patients with extramedullary multiple myeloma: multicenter real-world experience. Journal of Hematology & Oncology, 17, 8. https:\/\/doi.org\/10.1186\/s13045-024-01555-4","journal-title":"Journal of Hematology & Oncology"},{"key":"11228_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam, N., Trinklein, N. D., Buelow, B., Patterson, G. H., Ojha, N., & Kochenderfer, J. N. (2020). Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nature Communications, 11, 283. https:\/\/doi.org\/10.1038\/s41467-019-14119-9","journal-title":"Nature Communications"},{"issue":"Suppl 1","key":"11228_CR21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody, S., Htut, M., Lee, K. P., Bensinger, W., Devries, T., & Piasecki, J. (2018). JCARH125, anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: initial proof of concept results from a phase 1\/2 multicenter study. Blood, 132(Suppl 1), 957. https:\/\/doi.org\/10.1182\/blood-2018-99-113548","journal-title":"Blood"},{"issue":"Suppl","key":"11228_CR22","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","volume":"38","author":"S Mailankody","year":"2020","unstructured":"Mailankody, S., Jakubowiak, A. J., Htut, M., Costa, L. J., Lee, K., & Ganguly, S. (2020). Orvacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma: update of the phase 1\/2 EVOLVE study. Journal of Clinical Oncology, 38(Suppl), 8504. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8504","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR23","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., & Lancaster, E. (2019). B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 129, 2210\u20132221. https:\/\/doi.org\/10.1172\/JCI126397","journal-title":"Journal of Clinical Investigation"},{"key":"11228_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault, M. J., Bishop, M. R., Rosenblatt, J., de Lima, M., O\u2019Donnell, E., & Moreno, V. (2023). Phase 1 study of CART-ddBCMA for relapsed or refractory multiple myeloma. Blood Advances, 7, 768\u2013777. https:\/\/doi.org\/10.1182\/bloodadvances.2022007210","journal-title":"Blood Advances"},{"key":"11228_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1470-2045(23)00222-X","volume":"24","author":"A Oliver-Caldes","year":"2023","unstructured":"Oliver-Caldes, A., Jimenez, R., Espanol-Rego, M., Cibeira, M. T., Rosi\u00f1ol, L., & Gonzalez-Calle, V. (2023). ARI0002h, an academic BCMA-directed CAR T-cell therapy, in patients with relapsed\/refractory multiple myeloma: a multicentre, single-arm, phase 1\u20132 study. The Lancet Oncology, 24, 913\u2013924. https:\/\/doi.org\/10.1016\/S1470-2045(23)00222-X","journal-title":"The Lancet Oncology"},{"issue":"Suppl","key":"11228_CR26","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1200\/JCO.2024.42.16_suppl.7544","volume":"42","author":"CF Larrea","year":"2024","unstructured":"Larrea, C. F., Oliver-Caldes, A., & Jimenez, R. (2024). Updated results of ARI0002h in relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 42(Suppl), 7544. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7544","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13046-022-02540-w","volume":"15","author":"MJ Frigault","year":"2022","unstructured":"Frigault, M. J., Bishop, M. R., Rosenblatt, J., O\u2019Donnell, E., Moreno, V., & Chari, A. (2022). Dose fractionation of BCMA-directed CAR T-cell therapy in relapsed or refractory multiple myeloma. Journal of Hematology & Oncology, 15, 177. https:\/\/doi.org\/10.1186\/s13046-022-02540-w","journal-title":"Journal of Hematology & Oncology"},{"issue":"Suppl 1","key":"11228_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2018-99-119717","volume":"132","author":"S Mailankody","year":"2018","unstructured":"Mailankody, S., Ghosh, A., Staehr, M., Purdon, T. J., Roshal, M., & Halton, E. (2018). Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA-targeted CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood, 132(Suppl 1), 959. https:\/\/doi.org\/10.1182\/blood-2018-99-119717","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1182\/blood-2021-146518","volume":"138","author":"NS Raje","year":"2021","unstructured":"Raje, N. S., Costello, C., Terpos, E., Shah, N., Hari, P., & Berdeja, J. G. (2021). Safety and clinical activity of bb21217, a BCMA-directed CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma. Blood, 138(Suppl 1), 548. https:\/\/doi.org\/10.1182\/blood-2021-146518","journal-title":"Blood"},{"key":"11228_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., & Oluwole, O. O. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma. Nature Medicine, 29, 422\u2013429. https:\/\/doi.org\/10.1038\/s41591-022-02182-7","journal-title":"Nature Medicine"},{"key":"11228_CR31","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-025-65267-0","volume":"16","author":"YD Tseng","year":"2025","unstructured":"Tseng, Y. D., Lacey, S. F., & Lee, J. (2025). Safety and efficacy of allogeneic BCMA-directed CAR T cells in relapsed\/refractory multiple myeloma. Nature Communications, 16, 10232. https:\/\/doi.org\/10.1038\/s41467-025-65267-0","journal-title":"Nature Communications"},{"key":"11228_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/cells13020216","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez, C., Rafiq, S., Maude, S. L., June, C. H., & Posey, A. D. Jr. (2024). Allogeneic CAR T cells for cancer immunotherapy: recent advances and future directions. Cells, 13, 216. https:\/\/doi.org\/10.3390\/cells13020216","journal-title":"Cells"},{"key":"11228_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio, C., Murray, R., Naniong, M., Lumpkin, A., Lee, G., & Zhou, Y. (2025). Allogeneic CAR T-cell therapies for cancer. Nature Reviews Clinical Oncology, 22, 91\u2013108. https:\/\/doi.org\/10.1038\/s41571-024-00959-y","journal-title":"Nature Reviews Clinical Oncology"},{"key":"11228_CR34","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D., Li, Y., Basar, R., Rondon, G., Daher, M., & Rezvani, K. (2024). Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19-positive B cell tumours. Nature Medicine, 30, 772\u2013784. https:\/\/doi.org\/10.1038\/s41591-023-02785-8","journal-title":"Nature Medicine"},{"key":"11228_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., & Brentjens, R. J. (2022). Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews Clinical Oncology, 19, 342\u2013355. https:\/\/doi.org\/10.1038\/s41571-022-00607-3","journal-title":"Nature Reviews Clinical Oncology"},{"key":"11228_CR36","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.transci.2023.103828","volume":"62","author":"I Pessach","year":"2023","unstructured":"Pessach, I., & Nagler, A. (2023). Leukapheresis for CAR-T cell production in heavily pretreated hematological malignancies. Transfusion and Apheresis Science, 62, 103828. https:\/\/doi.org\/10.1016\/j.transci.2023.103828","journal-title":"Transfusion and Apheresis Science"},{"key":"11228_CR37","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1182\/blood.2024024523","volume":"145","author":"CJ Nicolai","year":"2025","unstructured":"Nicolai, C. J., Wolf, J., Chang, I. C., Kirschbaum, M., Burke, J., & Zbornik, E. A. (2025). In vivo generation of CAR T cells in non-human primates using CD8-targeted lentiviral vectors. Blood, 145, 1138\u20131149. https:\/\/doi.org\/10.1182\/blood.2024024523","journal-title":"Blood"},{"key":"11228_CR38","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"405","author":"J Xu","year":"2025","unstructured":"Xu, J., Chen, L. J., Yang, S. S., Sun, Y., Wu, W., & Liu, Y. F. (2025). In vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. The Lancet, 405, 1876\u20131887. https:\/\/doi.org\/10.1016\/S0140-6736(25)01030-X","journal-title":"The Lancet"},{"key":"11228_CR39","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur, M. K., Fulciniti, M., Aktas Samur, A., Bazarbachi, A. H., Tai, Y. T., & Prabhala, R. (2021). Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nature Communications, 12, 868. https:\/\/doi.org\/10.1038\/s41467-021-21177-5","journal-title":"Nature Communications"},{"key":"11228_CR40","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Via","year":"2021","unstructured":"Da Via, M. C., Dietrich, O., Truger, M., Arampatzi, P., Duell, J., & Heidemeier, A. (2021). Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nature Medicine, 27, 616\u2013619. https:\/\/doi.org\/10.1038\/s41591-021-01245-5","journal-title":"Nature Medicine"},{"key":"11228_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","volume":"102","author":"M Ghermezi","year":"2017","unstructured":"Ghermezi, M., Li, M., Vardanyan, S., Harutyunyan, N. M., Gottlieb, J., & Berenson, A. (2017). Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica, 102, 785\u2013795. https:\/\/doi.org\/10.3324\/haematol.2016.150896","journal-title":"Haematologica"},{"key":"11228_CR42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E., Li, M., Kitto, A., Li, J., Wang, C. S., & Kirk, D. T. (2012). Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. British Journal of Haematology, 158, 727\u2013738. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09241.x","journal-title":"British Journal of Haematology"},{"key":"11228_CR43","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan, A. J., Pont, M., Sather, B. D., Turtle, C. J., Till, B. G., & Libby, E. N. (2023). Gamma-secretase inhibitor in combination with BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma. The Lancet Oncology, 24, 811\u2013822. https:\/\/doi.org\/10.1016\/S1470-2045(23)00246-2","journal-title":"The Lancet Oncology"},{"issue":"Suppl 1","key":"11228_CR44","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1182\/blood-2021-154170","volume":"138","author":"AJ Cowan","year":"2021","unstructured":"Cowan, A. J., Pont, M., Sather, B. D., Turtle, C. J., Till, B. G., & Libby, E. N. (2021). Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor. Blood, 138(Suppl 1), 551. https:\/\/doi.org\/10.1182\/blood-2021-154170","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR45","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1182\/blood-2023-187349","volume":"142","author":"DM Rieger","year":"2023","unstructured":"Rieger, D. M., Goldsmith, S. R., & Long, K. (2023). BCMA expression and ubiquitin-proteasome regulation in multiple myeloma after BCMA-directed therapy. Blood, 142(Suppl 1), 4731. https:\/\/doi.org\/10.1182\/blood-2023-187349","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-137650","volume":"136","author":"N Leblay","year":"2020","unstructured":"Leblay, N., Maity, R., Barwick, B. G., Weitzner, B. D., Gupta, V. A., & Moon, E. K. (2020). Cite-seq profiling of plasma cells from multiple myeloma patients after BCMA CAR T cell therapy. Blood, 136(Suppl 1), 41\u201342. https:\/\/doi.org\/10.1182\/blood-2020-137650","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR47","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1182\/blood-2021-150923","volume":"138","author":"DT Melnekoff","year":"2021","unstructured":"Melnekoff, D. T., Ho, M., Ghermezi, M., Mei, M., O\u2019Donnell, E., & Yin, J. (2021). Single-cell analysis identifies immune and myeloma cell features associated with response to BCMA CAR T-cell therapy. Blood, 138(Suppl 1), 3821. https:\/\/doi.org\/10.1182\/blood-2021-150923","journal-title":"Blood"},{"key":"11228_CR48","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"EW Meermeier","year":"2021","unstructured":"Meermeier, E. W., Welsh, S. J., Sharik, M. E., Du, M. T., Garbitt, V. M., & Riggs, D. L. (2021). Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discovery, 2, 354\u2013369. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0038","journal-title":"Blood Cancer Discovery"},{"key":"11228_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1158\/2643-3230.BCD-24-0118","volume":"5","author":"D Fandrei","year":"2024","unstructured":"Fandrei, D., Seiffert, S., Rade, M., Gagelmann, N., Kreuz, M., & Born, P. (2024). Sequential administration of bispecific antibodies and anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma. Blood Cancer Discovery, 5, 315\u2013323. https:\/\/doi.org\/10.1158\/2643-3230.BCD-24-0118","journal-title":"Blood Cancer Discovery"},{"key":"11228_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan, D., Gurney, M., Keggins, A., & O\u2019Dwyer, M. E. (2024). CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer Journal, 14, 179. https:\/\/doi.org\/10.1038\/s41408-024-01191-8","journal-title":"Blood Cancer Journal"},{"key":"11228_CR51","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41375-024-02482-6","volume":"38","author":"LJ Costa","year":"2024","unstructured":"Costa, L. J., Chhabra, S., Medvedova, E., Dholaria, B., Dhakal, B., & Vogl, D. T. (2024). International Myeloma Working Group immunotherapy sequencing recommendations for relapsed\/refractory multiple myeloma. Leukemia, 38, 2285\u20132297. https:\/\/doi.org\/10.1038\/s41375-024-02482-6","journal-title":"Leukemia"},{"key":"11228_CR52","doi-asserted-by":"publisher","first-page":"e70260","DOI":"10.1002\/hem3.70260","volume":"8","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk, N. W. C. J., Dimopoulos, M. A., & Mateos, M. V. (2024). Treatment sequencing in relapsed\/refractory multiple myeloma in the era of T-cell redirecting therapies: European Myeloma Network recommendations. HemaSphere, 8, e70260. https:\/\/doi.org\/10.1002\/hem3.70260","journal-title":"HemaSphere"},{"key":"11228_CR53","doi-asserted-by":"publisher","first-page":"2613505","DOI":"10.1080\/16078454.2026.2613505","volume":"31","author":"Y Zhou","year":"2026","unstructured":"Zhou, Y., Xie, X., Feng, K., Cao, W., & Zhang, D. (2026). The efficacy and safety of CAR-T therapy in relapsed or refractory multiple myeloma patients: a systematic review and meta-analysis. Hematology, 31, 2613505. https:\/\/doi.org\/10.1080\/16078454.2026.2613505","journal-title":"Hematology"},{"key":"11228_CR54","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/03007995.2026.2660494","volume":"42","author":"DK Hansen","year":"2026","unstructured":"Hansen, D. K., Puglianini, C., Grajales-Cruz, O. A., Nagar, A., Ghosh, S. P., S., & Fan, L. (2026). Clinical outcomes with ciltacabtagene autoleucel among patients with relapsed\/refractory multiple myeloma after four or more prior lines of therapy overall and among subgroups based on age, frailty, and CRAB symptoms. Current Medical Research and Opinion, 42, 227\u2013235. https:\/\/doi.org\/10.1080\/03007995.2026.2660494","journal-title":"Current Medical Research and Opinion"},{"key":"11228_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-026-01496-w","volume":"16","author":"DK Hansen","year":"2026","unstructured":"Hansen, D. K., Dima, D., Mian, H., Devos, J., Brazauskas, R., & Oloyede, T. (2026). Safety and efficacy of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma: a CIBMTR study. Blood Cancer Journal, 16, 80. https:\/\/doi.org\/10.1038\/s41408-026-01496-w","journal-title":"Blood Cancer Journal"},{"key":"11228_CR56","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s12325-025-03479-y","volume":"43","author":"N Lopez-Mu\u00f1oz","year":"2026","unstructured":"Lopez-Mu\u00f1oz, N., Bar, N., Diels, J., van Sanden, S., Mendes, J., Lee, S., Hernando, T., Lendvai, N., Patel, N., Ishida, T., Er, J., & Harrison, S. J. (2026). Ciltacabtagene autoleucel versus idecabtagene vicleucel in triple-class-exposed relapsed\/refractory multiple myeloma with 2\u20134 prior lines of therapy: Updated matching-adjusted indirect comparison. Advances in Therapy, 43, 1327\u20131340. https:\/\/doi.org\/10.1007\/s12325-025-03479-y","journal-title":"Advances in Therapy"},{"key":"11228_CR57","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/cancers18061013","volume":"18","author":"C Filippatos","year":"2026","unstructured":"Filippatos, C., Ntanasis-Stathopoulos, I., Briasoulis, A., Malandrakis, P., Gavriatopoulou, M., & Terpos, E. (2026). Real-world experience with approved CAR T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel in 1272 relapsed\/refractory multiple myeloma patients. Cancers, 18, 1013. https:\/\/doi.org\/10.3390\/cancers18061013","journal-title":"Cancers"},{"key":"11228_CR58","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","volume":"32","author":"N An","year":"2026","unstructured":"An, N., Wang, D., & Zhang, P. (2026). In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study. Nature Medicine, 32, 1257\u20131266. https:\/\/doi.org\/10.1038\/s41591-026-04244-6","journal-title":"Nature Medicine"},{"key":"11228_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri, C. J., Ahmed, N., Dima, D., Bumma, N., Patel, K. K., & Shune, L. (2023). Real-world experience of idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma after prior BCMA-targeted therapy. Blood Cancer Journal, 13, 117. https:\/\/doi.org\/10.1038\/s41408-023-00886-8","journal-title":"Blood Cancer Journal"},{"key":"11228_CR60","doi-asserted-by":"publisher","first-page":"308e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima, D., Richter, J., Vij, R., Costello, C., Bumma, N., & Cohen, A. D. (2024). Real-world safety and efficacy of teclistamab in relapsed\/refractory multiple myeloma. Transplantation and Cellular Therapy, 30, 308e1\u201330308.e8.https:\/\/doi.org\/10.1016\/j.jtct.2023.12.016","journal-title":"Transplantation and Cellular Therapy"},{"key":"11228_CR61","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen, A. D., Parekh, S., Santomasso, B. D., Raje, N., Berdeja, J. G., & Shah, N. (2023). Ciltacabtagene autoleucel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood, 141, 219\u2013230. https:\/\/doi.org\/10.1182\/blood.2022015526","journal-title":"Blood"},{"key":"11228_CR62","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., & Carstens, E. J. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387, 1196\u20131206. https:\/\/doi.org\/10.1056\/NEJMoa2209900","journal-title":"New England Journal of Medicine"},{"key":"11228_CR63","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., & Wang, Y. (2023). GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma (OriCAR-017): a single-arm, phase 1 trial. The Lancet Haematology, 10, e108\u2013e117. https:\/\/doi.org\/10.1016\/S2352-3026(22)00372-6","journal-title":"The Lancet Haematology"},{"issue":"Suppl 1","key":"11228_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood-2023-181857","volume":"142","author":"S Bal","year":"2023","unstructured":"Bal, S., Mailankody, S., & Lesokhin, A. M. (2023). BMS-986393, a GPRC5D-directed CAR T-cell therapy, in relapsed\/refractory multiple myeloma. Blood, 142(Suppl 1), 219. https:\/\/doi.org\/10.1182\/blood-2023-181857","journal-title":"Blood"},{"key":"11228_CR65","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1182\/blood.2025030559","volume":"147","author":"M Pan","year":"2026","unstructured":"Pan, M., Wang, D., Xu, J., Jin, S., Wang, Y., & Tao, Y. (2026). The fully human anti-GPRC5D CAR T-cell therapy RD118 induces durable remissions in relapsed\/refractory multiple myeloma. Blood, 147, 513\u2013519. https:\/\/doi.org\/10.1182\/blood.2025030559","journal-title":"Blood"},{"key":"11228_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood.2025031961","volume":"147","author":"S Al Hadidi","year":"2026","unstructured":"Al Hadidi, S. (2026). The post-BCMA playbook: RD118 GPRC5D CAR T cells for myeloma. Blood, 147, 474\u2013476. https:\/\/doi.org\/10.1182\/blood.2025031961","journal-title":"Blood"},{"key":"11228_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-026-01474-2","volume":"16","author":"MS Rana","year":"2026","unstructured":"Rana, M. S., Fernandez-Pol, S., & Jensen, A. (2026). Dynamics of BCMA expression in patients with relapsed\/refractory multiple myeloma receiving BCMA-directed CAR-T therapy. Blood Cancer Journal, 16, 79. https:\/\/doi.org\/10.1038\/s41408-026-01474-2","journal-title":"Blood Cancer Journal"},{"key":"11228_CR68","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.ccell.2025.10.014","volume":"44","author":"M Rade","year":"2026","unstructured":"Rade, M., Fandrei, D., & Kreuz, M. (2026). A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T-cell therapy in multiple myeloma. Cancer Cell, 44, 586\u2013603e9. https:\/\/doi.org\/10.1016\/j.ccell.2025.10.014","journal-title":"Cancer Cell"},{"key":"11228_CR69","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Usmani, S. Z., & Yong, K. (2021). CAR T-cell therapy for multiple myeloma: state of the art and prospects. The Lancet Haematology, 8, e446\u2013e461. https:\/\/doi.org\/10.1016\/S2352-3026(21)00057-0","journal-title":"The Lancet Haematology"},{"key":"11228_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh, P. J., & Chng, W. J. (2021). CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer Journal, 11, 84. https:\/\/doi.org\/10.1038\/s41408-021-00469-5","journal-title":"Blood Cancer Journal"},{"key":"11228_CR71","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/10428194.2023.2276676","volume":"65","author":"T Scheller","year":"2024","unstructured":"Scheller, T., Schmidt, C., Einsele, H., & Mailankody, S. (2024). BCMA CAR-T-cell therapy in relapsed\/refractory multiple myeloma: ready for take-off. Leukemia & Lymphoma, 65, 55\u201370. https:\/\/doi.org\/10.1080\/10428194.2023.2276676","journal-title":"Leukemia & Lymphoma"},{"key":"11228_CR72","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.3390\/ijms25094996","volume":"25","author":"DS Pereira","year":"2024","unstructured":"Pereira, D. S., Rejeski, K., & Gagelmann, N. (2024). Efficacy and safety of CAR T-cell therapies in multiple myeloma: a systematic review and meta-analysis. International Journal of Molecular Sciences, 25, 4996. https:\/\/doi.org\/10.3390\/ijms25094996","journal-title":"International Journal of Molecular Sciences"},{"key":"11228_CR73","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","volume":"73","author":"A Parikh","year":"2023","unstructured":"Parikh, A., Gauthier, J., Turtle, C. J., & Maloney, D. G. (2023). Chimeric antigen receptor T-cell therapy for multiple myeloma: a comprehensive review. CA: A Cancer Journal for Clinicians, 73, 275\u2013296. https:\/\/doi.org\/10.3322\/caac.21771","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"11228_CR74","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1007\/s00277-025-06524-6","volume":"104","author":"P Techaapornkun","year":"2025","unstructured":"Techaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., & Thu, M. S. (2025). Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed\/refractory multiple myeloma: a meta-analysis of interventional and real-world studies. Annals of Hematology, 104, 4791\u20134809. https:\/\/doi.org\/10.1007\/s00277-025-06524-6","journal-title":"Annals of Hematology"},{"key":"11228_CR75","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s41375-026-02933-2","volume":"40","author":"M Merz","year":"2026","unstructured":"Merz, M., Jurgens, E., Fandrei, D., Usmani, S. Z., & Mailankody, S. (2026). Pharmacokinetics of CAR T cells in multiple myeloma: the good, the bad, and the ugly. Leukemia, 40, 872\u2013879. https:\/\/doi.org\/10.1038\/s41375-026-02933-2","journal-title":"Leukemia"},{"key":"11228_CR76","doi-asserted-by":"publisher","first-page":"1613265","DOI":"10.3389\/fimmu.2025.1613265","volume":"16","author":"NT Iannozzi","year":"2025","unstructured":"Iannozzi, N. T., Giuliani, N., & Storti, P. (2025). Deciphering the bone marrow microenvironment\u2019s role in multiple myeloma immunotherapy resistance. Frontiers in Immunology, 16, 1613265. https:\/\/doi.org\/10.3389\/fimmu.2025.1613265","journal-title":"Frontiers in Immunology"},{"key":"11228_CR77","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005621","volume":"136","author":"B Paiva","year":"2020","unstructured":"Paiva, B., Puig, N., Cedena, M. T., de Jong, B., Ruiz, Y., & Rapado, I. (2020). Measurable residual disease by next-generation flow cytometry in multiple myeloma. Blood, 136, 936\u2013947. https:\/\/doi.org\/10.1182\/blood.2020005621","journal-title":"Blood"},{"key":"11228_CR78","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","volume":"31","author":"AC Rawstron","year":"2013","unstructured":"Rawstron, A. C., Child, J. A., de Tute, R. M., Davies, F. E., Gregory, W. M., & Bell, S. E. (2013). Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma. Journal of Clinical Oncology, 31, 2540\u20132547. https:\/\/doi.org\/10.1200\/JCO.2012.46.2119","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR79","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2018-01-826628","volume":"132","author":"H Avet-Loiseau","year":"2018","unstructured":"Avet-Loiseau, H., Corre, J., Lauwers-Cances, V., Chretien, M. L., Robillard, N., & Leleu, X. (2018). Evaluation of minimal residual disease in multiple myeloma with next-generation sequencing. Blood, 132, 1092\u20131099. https:\/\/doi.org\/10.1182\/blood-2018-01-826628","journal-title":"Blood"},{"key":"11228_CR80","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot, A., Lauwers-Cances, V., Corre, J., Robillard, N., Hulin, C., & Chretien, M. L. (2018). Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood, 132, 2456\u20132464. https:\/\/doi.org\/10.1182\/blood-2018-06-858613","journal-title":"Blood"},{"key":"11228_CR81","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Buechner, J., & Bethge, W. (2023). The CAR-HEMATOTOX score identifies hematologic toxicity after CAR T-cell therapy. Journal of Hematology & Oncology, 16, 98. https:\/\/doi.org\/10.1186\/s13045-023-01465-x","journal-title":"Journal of Hematology & Oncology"},{"key":"11228_CR82","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann, N., Riecken, K., Wolschke, C., Ayuk, F., Kroger, N., & Bethge, W. (2024). Development and validation of a prediction model for outcome after BCMA-directed CAR T-cell therapy in multiple myeloma. Journal of Clinical Oncology, 42, 1665\u20131677. https:\/\/doi.org\/10.1200\/JCO.23.02232","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR83","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3324\/haematol.2022.282510","volume":"109","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann, N., Riecken, K., Wolschke, C., Ayuk, F., Kroger, N., & Bethge, W. (2024). Impact of high-risk cytogenetics on outcomes after BCMA CAR T-cell therapy in multiple myeloma: a systematic review and meta-analysis. Haematologica, 109, 1522\u20131532. https:\/\/doi.org\/10.3324\/haematol.2022.282510","journal-title":"Haematologica"},{"key":"11228_CR84","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., & Facon, T. (2012). Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1782\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1114138","journal-title":"New England Journal of Medicine"},{"key":"11228_CR85","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., & Richardson, P. G. (2012). Lenalidomide after stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 366, 1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMoa1114083","journal-title":"New England Journal of Medicine"},{"key":"11228_CR86","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"SA Holstein","year":"2017","unstructured":"Holstein, S. A., Jung, S. H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., & Hassoun, H. (2017). Updated analysis of CALGB 100104: lenalidomide versus placebo maintenance therapy after autologous stem cell transplantation. Journal of Clinical Oncology, 35, 3279\u20133289. https:\/\/doi.org\/10.1200\/JCO.2017.72.6679","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR87","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","volume":"103","author":"R LeBlanc","year":"2004","unstructured":"LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., & Mitsiades, N. (2004). Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood, 103, 1787\u20131790. https:\/\/doi.org\/10.1182\/blood-2003-02-0361","journal-title":"Blood"},{"key":"11228_CR88","doi-asserted-by":"publisher","first-page":"20476","DOI":"10.18632\/oncotarget.24944","volume":"9","author":"K Fostier","year":"2018","unstructured":"Fostier, K., Caers, J., & Meuleman, N. (2018). Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden. Oncotarget, 9, 20476\u201320489. https:\/\/doi.org\/10.18632\/oncotarget.24944","journal-title":"Oncotarget"},{"key":"11228_CR89","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., & Hardan, I. (2015). Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. Journal of Clinical Oncology, 33, 3459\u20133466. https:\/\/doi.org\/10.1200\/JCO.2014.60.2466","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","volume":"24","author":"X Wang","year":"2018","unstructured":"Wang, X., Walter, M., Urak, R., Weng, L., Huynh, C., & Lim, L. (2018). Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clinical Cancer Research, 24, 106\u2013119. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0344","journal-title":"Clinical Cancer Research"},{"key":"11228_CR91","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ajh.26486","volume":"97","author":"X Shi","year":"2022","unstructured":"Shi, X., Yan, L., Shang, J., Qu, S., Kang, L., & Zhou, J. (2022). Tandem autologous transplantation and combined infusion of CD19- and BCMA-specific CAR T cells followed by lenalidomide maintenance in high-risk multiple myeloma. American Journal of Hematology, 97, 537\u2013547. https:\/\/doi.org\/10.1002\/ajh.26486","journal-title":"American Journal of Hematology"},{"key":"11228_CR92","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3390\/cancers12040924","volume":"12","author":"H Tamura","year":"2020","unstructured":"Tamura, H., Ishibashi, M., Sunakawa, M., & Inokuchi, K. (2020). PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma. Cancers, 12, 924. https:\/\/doi.org\/10.3390\/cancers12040924","journal-title":"Cancers"},{"key":"11228_CR93","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/blood-2010-01-265975","volume":"116","author":"JJ Park","year":"2010","unstructured":"Park, J. J., Omiya, R., Matsumura, Y., Sakoda, Y., Kuramasu, A., & Augustine, M. M. (2010). B7-H1\/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood, 116, 1291\u20131298. https:\/\/doi.org\/10.1182\/blood-2010-01-265975","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR94","doi-asserted-by":"publisher","first-page":"10150","DOI":"10.1182\/blood-2022-157987","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva, B., Puig, N., & Cedena, M. T. (2022). Alnuctamab combined with CELMoD agents in multiple myeloma: immune profiling and early clinical observations. Blood, 140(Suppl 1), 10150. https:\/\/doi.org\/10.1182\/blood-2022-157987","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR95","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1182\/blood-2021-153871","volume":"138","author":"R Maity","year":"2021","unstructured":"Maity, R., Mishra, S., Gulati, S., Soto, J. A., Rosin, J., & Muralidharan, S. (2021). BCL2L1 armoring enhances persistence and function of BCMA CAR T cells in multiple myeloma. Blood, 138(Suppl 1), 1660. https:\/\/doi.org\/10.1182\/blood-2021-153871","journal-title":"Blood"},{"key":"11228_CR96","doi-asserted-by":"publisher","first-page":"101043","DOI":"10.1016\/j.blre.2023.101043","volume":"59","author":"PT Griffin","year":"2023","unstructured":"Griffin, P. T., & Holstein, S. A. (2023). CELMoDs in multiple myeloma: immunologic rationale and clinical development. Blood Reviews, 59, 101043. https:\/\/doi.org\/10.1016\/j.blre.2023.101043","journal-title":"Blood Reviews"},{"key":"11228_CR97","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00254-X","volume":"9","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G., Popat, R., Jagannath, S., Oriol, A., Bahlis, N., & Alsina, M. (2022). Iberdomide plus dexamethasone in heavily pretreated relapsed\/refractory multiple myeloma. The Lancet Haematology, 9, e822\u2013e832. https:\/\/doi.org\/10.1016\/S2352-3026(22)00254-X","journal-title":"The Lancet Haematology"},{"key":"11228_CR98","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., Jarari, E., Bertsch, L., U., & Salwender, H. (2012). Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma. Journal of Clinical Oncology, 30, 2946\u20132955. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR99","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","volume":"1","author":"N Korde","year":"2015","unstructured":"Korde, N., Roschewski, M., Zingone, A., Kwok, M., Manasanch, E. E., & Bhutani, M. (2015). Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide maintenance in newly diagnosed multiple myeloma. JAMA Oncology, 1, 746\u2013754. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2010","journal-title":"JAMA Oncology"},{"key":"11228_CR100","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"PG Richardson","year":"2019","unstructured":"Richardson, P. G., Bringhen, S., Voorhees, P., Plesner, T., Mellqvist, U. H., & Reeves, B. (2019). Isatuximab plus pomalidomide and low-dose dexamethasone in relapsed\/refractory multiple myeloma (ICARIA-MM). The Lancet, 394, 2096\u20132107. https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5","journal-title":"The Lancet"},{"key":"11228_CR101","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"M Attal","year":"2021","unstructured":"Attal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., & Spicka, I. (2021). Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma (IKEMA). The Lancet, 397, 2361\u20132371. https:\/\/doi.org\/10.1016\/S0140-6736(21)00592-4","journal-title":"The Lancet"},{"key":"11228_CR102","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1200\/JCO.23.01796","volume":"42","author":"P Moreau","year":"2024","unstructured":"Moreau, P., Dimopoulos, M. A., Mikhael, J., Yong, K., Capra, M., & Facon, T. (2024). Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma: IKEMA update. Journal of Clinical Oncology, 42, 2235\u20132246. https:\/\/doi.org\/10.1200\/JCO.23.01796","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR103","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos, M. V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., & Knop, S. (2018). Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. New England Journal of Medicine, 378, 518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"New England Journal of Medicine"},{"key":"11228_CR104","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., & Usmani, S. Z. (2016). Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. New England Journal of Medicine, 375, 1319\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"New England Journal of Medicine"},{"key":"11228_CR105","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., & Beksac, M. (2016). Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine, 375, 754\u2013766. https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"New England Journal of Medicine"},{"key":"11228_CR106","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., & Katodritou, E. (2021). Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma (APOLLO). The Lancet Oncology, 22, 801\u2013812. https:\/\/doi.org\/10.1016\/S1470-2045(21)00128-5","journal-title":"The Lancet Oncology"},{"key":"11228_CR107","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., & Bahlis, N. (2019). Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. New England Journal of Medicine, 380, 2104\u20132115. https:\/\/doi.org\/10.1056\/NEJMoa1817249","journal-title":"New England Journal of Medicine"},{"key":"11228_CR108","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson, P. G., Oriol, A., Larocca, A., Blad\u00e9, J., Cavo, M., & Rodriguez-Otero, P. (2021). Melflufen and dexamethasone in heavily pretreated relapsed\/refractory multiple myeloma (HORIZON). Journal of Clinical Oncology, 39, 757\u2013767. https:\/\/doi.org\/10.1200\/JCO.20.02259","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR109","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"397","author":"PG Richardson","year":"2021","unstructured":"Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., & Schjesvold, F. (2021). Selinexor, bortezomib, and dexamethasone for patients with multiple myeloma previously treated with bortezomib and lenalidomide (BOSTON). The Lancet, 397, 2165\u20132176. https:\/\/doi.org\/10.1016\/S0140-6736(20)32292-3","journal-title":"The Lancet"},{"key":"11228_CR110","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"JL Kaufman","year":"2017","unstructured":"Kaufman, J. L., Gasparetto, C., Mikhael, J., Moreau, P., Touzeau, C., & Facon, T. (2017). Efficacy and safety of venetoclax-based therapy in relapsed\/refractory multiple myeloma with t(11;14). Blood, 130, 2401\u20132409. https:\/\/doi.org\/10.1182\/blood-2017-06-788786","journal-title":"Blood"},{"key":"11228_CR111","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., & Gasparetto, C. (2020). Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma (BELLINI). The Lancet Oncology, 21, 1630\u20131642. https:\/\/doi.org\/10.1016\/S1470-2045(20)30525-8","journal-title":"The Lancet Oncology"},{"key":"11228_CR112","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel, J. F., Hungria, V. T. M., Yoon, S. S., Beksac, M., Dimopoulos, M. A., & Elghandour, A. (2014). Panobinostat plus bortezomib and dexamethasone in relapsed or relapsed\/refractory multiple myeloma (PANORAMA 1). The Lancet Oncology, 15, 1195\u20131206. https:\/\/doi.org\/10.1016\/S1470-2045(14)70440-1","journal-title":"The Lancet Oncology"},{"key":"11228_CR113","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(20)30149-1","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., & Chari, A. (2020). Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomized, open-label, phase 2 study. The Lancet Oncology, 21, 207\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(20)30149-1","journal-title":"The Lancet Oncology"},{"key":"11228_CR114","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"S Iida","year":"2023","unstructured":"Iida, S., Chng, W. J., & Moreau, P. (2023). Safety and efficacy of elranatamab in patients with relapsed\/refractory multiple myeloma. Nature Medicine, 29, 2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nature Medicine"},{"key":"11228_CR115","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.22.02830","volume":"41","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis, N. J., Raje, N. S., & Costello, C. (2023). MagnetisMM-3: elranatamab in relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 41, 3002\u20133013. https:\/\/doi.org\/10.1200\/JCO.22.02830","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR116","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","volume":"19","author":"S Trudel","year":"2018","unstructured":"Trudel, S., Lendvai, N., Popat, R., Voorhees, P. M., Reeves, B., & Libby, E. N. (2018). Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed\/refractory multiple myeloma. The Lancet Oncology, 19, 1641\u20131653. https:\/\/doi.org\/10.1016\/S1470-2045(18)30576-X","journal-title":"The Lancet Oncology"},{"key":"11228_CR117","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"AK Nooka","year":"2024","unstructured":"Nooka, A. K., Stockerl-Goldstein, K., & Quach, H. (2024). DREAMM-8: belantamab mafodotin plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma. New England Journal of Medicine, 391, 393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2403407","journal-title":"New England Journal of Medicine"},{"key":"11228_CR118","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2401318","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M. A., Bahlis, N. J., & Roussel, M. (2024). DREAMM-7: belantamab mafodotin, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma. New England Journal of Medicine, 391, 408\u2013421. https:\/\/doi.org\/10.1056\/NEJMoa2401318","journal-title":"New England Journal of Medicine"},{"key":"11228_CR119","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., & Oriol, A. (2022). Teclistamab in relapsed or refractory multiple myeloma. New England Journal of Medicine, 387, 495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478","journal-title":"New England Journal of Medicine"},{"key":"11228_CR120","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., & Rodriguez-Otero, P. (2022). Talquetamab, a T-cell redirecting GPRC5D bispecific antibody for multiple myeloma. New England Journal of Medicine, 387, 2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"New England Journal of Medicine"},{"key":"11228_CR121","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41408-023-00966-9","volume":"13","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P., Usmani, S. Z., Cohen, A. D., Delimpasi, S., & van de Donk, N. W. C. J. (2023). GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer Journal, 13, 159. https:\/\/doi.org\/10.1038\/s41408-023-00966-9","journal-title":"Blood Cancer Journal"},{"key":"11228_CR122","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.4049\/jimmunol.1202860","volume":"191","author":"A Franco","year":"2013","unstructured":"Franco, A., Dao, T., & Ridgeway, A. (2013). The Fc receptor-like 5 antigen is expressed by malignant plasma cells and is a candidate immunotherapy target. Journal of Immunology, 191, 2265\u20132272. https:\/\/doi.org\/10.4049\/jimmunol.1202860","journal-title":"Journal of Immunology"},{"issue":"Suppl 1","key":"11228_CR123","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/blood-2022-157547","volume":"140","author":"AM Lesokhin","year":"2022","unstructured":"Lesokhin, A. M., Levy, M. Y., & Dalovisio, A. P. (2022). Cevostamab, an FcRH5\/CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. Blood, 140(Suppl 1), 444. https:\/\/doi.org\/10.1182\/blood-2022-157547","journal-title":"Blood"},{"key":"11228_CR124","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1038\/s41467-023-39395-4","volume":"14","author":"S Jiang","year":"2023","unstructured":"Jiang, S., Jin, J., Hao, S., Yang, M., Chen, S., & Ruan, H. (2023). A novel FcRH5-directed CAR T-cell therapy for multiple myeloma. Nature Communications, 14, 3645. https:\/\/doi.org\/10.1038\/s41467-023-39395-4","journal-title":"Nature Communications"},{"key":"11228_CR125","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00277-022-05027-y","volume":"102","author":"S Ghandili","year":"2023","unstructured":"Ghandili, S., Becher, T., & Heidemeier, A. (2023). VTD-PACE and related intensive chemotherapy regimens as salvage therapy for relapsed\/refractory multiple myeloma. Annals of Hematology, 102, 1179\u20131192. https:\/\/doi.org\/10.1007\/s00277-022-05027-y","journal-title":"Annals of Hematology"},{"key":"11228_CR126","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3390\/cancers18040669","volume":"18","author":"J Davidson","year":"2026","unstructured":"Davidson, J., Kumar, A., Patel, A., Chen, I. Y., Butte, A. J., & Zack, T. (2026). Investigating CAR-T treatment access for multiple myeloma patients using real-world evidence. Cancers, 18, 669. https:\/\/doi.org\/10.3390\/cancers18040669","journal-title":"Cancers"},{"key":"11228_CR127","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","volume":"7","author":"EL Smith","year":"2019","unstructured":"Smith, E. L., Mailankody, S., Staehr, M., Wang, X., Senechal, B., & Purdon, T. J. (2019). BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy. Cancer Immunology Research, 7, 1047\u20131053. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0551","journal-title":"Cancer Immunology Research"},{"key":"11228_CR128","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.2025028597","volume":"145","author":"D Dutta","year":"2025","unstructured":"Dutta, D., Liu, J., Wen, K., Ray, A., Salatino, A., & Liu, X. (2025). A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma. Blood, 145, 2322\u20132335. https:\/\/doi.org\/10.1182\/blood.2025028597","journal-title":"Blood"},{"key":"11228_CR129","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., & Spicka, I. (2015). Elotuzumab therapy for relapsed or refractory multiple myeloma. New England Journal of Medicine, 373, 621\u2013631. https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"New England Journal of Medicine"},{"key":"11228_CR130","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V., San-Miguel, J., Dimopoulos, M. A., Moreau, P., Hungria, V., & Oriol, A. (2020). Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma. The Lancet, 395, 132\u2013141. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3","journal-title":"The Lancet"},{"key":"11228_CR131","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., & Rodriguez, C. (2020). Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: GRIFFIN. Blood, 136, 936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"key":"11228_CR132","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood.2021012811","volume":"139","author":"R Sakemura","year":"2022","unstructured":"Sakemura, R., Terakura, S., Watanabe, K., Julamanee, J., Takagi, E., & Miyao, K. (2022). A novel strategy to target cancer-associated fibroblasts with CAR T-cell therapy. Blood, 139, 3708\u20133721. https:\/\/doi.org\/10.1182\/blood.2021012811","journal-title":"Blood"},{"issue":"Suppl 1","key":"11228_CR133","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1182\/blood-2022-162682","volume":"140","author":"C Ferment","year":"2022","unstructured":"Ferment, C., Cantero, A., & Gauthier, J. (2022). FENIX: a phase 1 study of BCMA-directed CAR T cells in relapsed\/refractory multiple myeloma. Blood, 140(Suppl 1), 4590. https:\/\/doi.org\/10.1182\/blood-2022-162682","journal-title":"Blood"},{"issue":"Suppl","key":"11228_CR134","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","volume":"41","author":"AS Sperling","year":"2023","unstructured":"Sperling, A. S., Shah, N. N., & Jagannath, S. (2023). PHE885, a fully human BCMA-directed CAR T-cell therapy, in relapsed\/refractory multiple myeloma. Journal of Clinical Oncology, 41(Suppl), 8004. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8004","journal-title":"Journal of Clinical Oncology"},{"key":"11228_CR135","doi-asserted-by":"publisher","first-page":"504e1","DOI":"10.1016\/j.jtct.2023.05.016","volume":"29","author":"A Zafar","year":"2023","unstructured":"Zafar, A., Huang, C. Y., Lo, M., Arora, S., Chung, A., & Wong, S. W. (2023). Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T-cell therapy in myeloma. Transplantation and Cellular Therapy, 29, 504e1. https:\/\/doi.org\/10.1016\/j.jtct.2023.05.016","journal-title":"Transplantation and Cellular Therapy"},{"issue":"Suppl 1","key":"11228_CR136","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1016\/j.htct.2021.10.460","volume":"43","author":"D Madduri","year":"2021","unstructured":"Madduri, D., Berdeja, J. G., Usmani, S. Z., Jakubowiak, A., Agha, M., & Cohen, A. D. (2021). CARTITUDE-1: phase 1b\/2 study of ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. Hematology Transfusion and Cell Therapy, 43(Suppl 1), S267. https:\/\/doi.org\/10.1016\/j.htct.2021.10.460","journal-title":"Hematology Transfusion and Cell Therapy"},{"key":"11228_CR137","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27380","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. (2024). Multiple myeloma: 2024 update on diagnosis, risk-stratification and management. American Journal of Hematology, 99, 1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27380","journal-title":"American Journal of Hematology"},{"key":"11228_CR138","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41409-026-02905-1","volume":"61","author":"L Rasche","year":"2026","unstructured":"Rasche, L., Krauth, M. T., & Agis, H. (2026). Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma. Bone Marrow Transplantation, 61, 785\u2013790. https:\/\/doi.org\/10.1038\/s41409-026-02905-1","journal-title":"Bone Marrow Transplantation"},{"key":"11228_CR139","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1182\/bloodadvances.2024015732","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking, J. H., Gagelmann, N., & Rades, D. (2025). Bridging intensity before BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma. Blood Advances, 9, 1516\u20131527. https:\/\/doi.org\/10.1182\/bloodadvances.2024015732","journal-title":"Blood Advances"},{"key":"11228_CR140","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","volume":"5","author":"VE Kennedy","year":"2021","unstructured":"Kennedy, V. E., Wong, S. W., Salem, J. E., Maude, S. L., Cohen, A. D., & Ruella, M. (2021). Macrophage activation syndrome-like manifestations after BCMA-directed CAR T-cell therapy in multiple myeloma. Blood Advances, 5, 5344\u20135348. https:\/\/doi.org\/10.1182\/bloodadvances.2021005020","journal-title":"Blood Advances"},{"key":"11228_CR141","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/bjh.18045","volume":"198","author":"D Swan","year":"2022","unstructured":"Swan, D., Routledge, D., Harrison, S. J., & O\u2019Dwyer, M. E. (2022). Hemostatic complications of BCMA-directed CAR T-cell therapy in multiple myeloma. British Journal of Haematology, 198, 676\u2013681. https:\/\/doi.org\/10.1111\/bjh.18045","journal-title":"British Journal of Haematology"},{"key":"11228_CR142","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen, A. D., Parekh, S., Santomasso, B. D., Raje, N., Berdeja, J. G., & Shah, N. (2022). Incidence and management of CAR T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel. Blood Cancer Journal, 12, 32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1","journal-title":"Blood Cancer Journal"},{"key":"11228_CR143","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1182\/blood.2023020571","volume":"143","author":"P Karschnia","year":"2024","unstructured":"Karschnia, P., Jordan, J. T., Forst, D. A., Arrillaga-Romany, I. C., Batchelor, T. T., & Maus, M. V. (2024). Clinical presentation, management and biomarkers of neurologic toxicities after CAR T-cell therapy. Blood, 143, 1347\u20131357. https:\/\/doi.org\/10.1182\/blood.2023020571","journal-title":"Blood"},{"key":"11228_CR144","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O., Aleman, A., Upadhyaya, B., Schnakenberg, S., Madduri, D., & Gavane, S. (2021). Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 27, 2099\u20132103. https:\/\/doi.org\/10.1038\/s41591-021-01564-7","journal-title":"Nature Medicine"},{"key":"11228_CR145","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1080\/10428194.2021.1907373","volume":"62","author":"V Huynh","year":"2021","unstructured":"Huynh, V., Gormley, N., Short, K. D., Thomas, S. K., & Shah, N. (2021). Outcomes of D(T)PACE-based salvage therapy in multiple myeloma with extramedullary disease. Leukemia & Lymphoma, 62, 2590\u20132598. https:\/\/doi.org\/10.1080\/10428194.2021.1907373","journal-title":"Leukemia & Lymphoma"},{"key":"11228_CR146","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","volume":"27","author":"SH Manjunath","year":"2021","unstructured":"Manjunath, S. H., Cohen, A. D., Lacey, S. F., Davis, M. M., Garfall, A. L., & Melenhorst, J. J. (2021). The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma. Clinical Cancer Research, 27, 6580\u20136590. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0308","journal-title":"Clinical Cancer Research"},{"key":"11228_CR147","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., & Huff, C. A. (2019). Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. New England Journal of Medicine, 381, 727\u2013738. https:\/\/doi.org\/10.1056\/NEJMoa1903455","journal-title":"New England Journal of Medicine"},{"key":"11228_CR148","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/pathogens14020170","volume":"14","author":"P Evangelidis","year":"2025","unstructured":"Evangelidis, P., Tragiannidis, K., Vyzantiadis, A., Evangelidis, N., Kalmoukos, P., & Vyzantiadis, T. A. (2025). Invasive fungal disease after chimeric antigen receptor-T immunotherapy in adult and pediatric patients. Pathogens, 14, 170. https:\/\/doi.org\/10.3390\/pathogens14020170","journal-title":"Pathogens"},{"key":"11228_CR149","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12967-026-08302-y","volume":"24","author":"X Li","year":"2026","unstructured":"Li, X., Liu, C., & Niu, S. (2026). Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed\/refractory multiple myeloma with extramedullary disease. Journal of Translational Medicine, 24, 506. https:\/\/doi.org\/10.1186\/s12967-026-08302-y","journal-title":"Journal of Translational Medicine"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11228-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11228-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11228-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:02:59Z","timestamp":1793300579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11228-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":149,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11228"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11228-z","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}